ARDS - Aridis Pharmaceuticals, Inc. Stock Price and Quote

ARDS [NASD]

Index	-	P/E	-	EPS (ttm)	-1.93	Insider Own	31.53%	Shs Outstand	17.70M	Perf Week	-16.27%
Market Cap	12.70M	Forward P/E	-	EPS next Y	-0.81	Insider Trans	0.00%	Shs Float	17.60M	Perf Month	-32.69%
Income	-32.80M	PEG	-	EPS next Q	-0.41	Inst Own	10.20%	Short Float / Ratio	17.39% / 1.87	Perf Quarter	-60.99%
Sales	2.90M	P/S	4.38	EPS this Y	-54.70%	Inst Trans	3.26%	Short Interest	3.06M	Perf Half Y	-59.03%
Book/sh	-2.02	P/B	-	EPS next Y	54.00%	ROA	-165.20%	Target Price	6.00	Perf Year	-80.71%
Cash/sh	0.05	P/C	6.69	EPS next 5Y	-	ROE	134.90%	52W Range	0.33 - 2.77	Perf YTD	-70.91%
Dividend	-	P/FCF	-	EPS past 5Y	-27.30%	ROI	591.40%	52W High	-87.61%	Beta	1.08
Dividend %	-	Quick Ratio	0.20	Sales past 5Y	-7.50%	Gross Margin	-	52W Low	4.03%	ATR	0.06
Employees	34	Current Ratio	0.20	Sales Q/Q	-20.00%	Oper. Margin	-	RSI (14)	31.10	Volatility	9.19% 12.99%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	76.00%	Profit Margin	-	Rel Volume	0.00	Prev Close	0.34
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	1.63M	Price	0.34
Recom	2.30	SMA20	-19.87%	SMA50	-42.51%	SMA200	-68.93%	Volume	0	Change	0.00%

Feb-19-20

Initiated

ROTH Capital

Buy

$18

Mar-14-23 09:45AM	Aridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common Stock GlobeNewswire -22.57%
Mar-13-23 11:15AM	Why Aridis Pharmaceuticals Shares Are Soaring Today Benzinga +18.66%
08:00AM	Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patients GlobeNewswire
Feb-17-23 08:00AM	Interviews with Rail Vision, Aridis Pharmaceuticals, and Digital Ally to Air on Bloomberg U.S. on the RedChip Money Report(R) ACCESSWIRE
Feb-15-23 07:22AM	When Will Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Breakeven? Simply Wall St.
05:34PM	Loading…
Feb-06-23 05:34PM	In virtuous cycle, foundation uses drug royalty riches to back new cystic fibrosis drug research in Bay Area American City Business Journals -5.16%
Feb-01-23 09:55AM	Here's Why Aridis Pharmaceuticals (ARDS) Is a Great 'Buy the Bottom' Stock Now Zacks
Jan-25-23 04:05PM	Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP) GlobeNewswire +46.43%
Jan-17-23 04:30PM	New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update GlobeNewswire
Dec-28-22 08:30AM	Aridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25 GlobeNewswire -10.04%
Dec-12-22 08:05AM	(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation GlobeNewswire +8.33%
07:00AM	Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation GlobeNewswire
Dec-05-22 07:00AM	Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical GlobeNewswire
Nov-30-22 07:00AM	Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patients GlobeNewswire
Nov-22-22 09:10AM	Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases GlobeNewswire
07:55PM	Loading…
Nov-21-22 07:55PM	Aridis Pharmaceuticals (ARDS) Reports Q3 Loss, Misses Revenue Estimates Zacks +9.87%
06:30PM	Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update GlobeNewswire
Oct-12-22 12:16PM	DICE Therapeutics (DICE) Up on Top-Line Data From Psoriasis Study Zacks
Oct-11-22 05:32PM	scPharmaceuticals (SCPH) Plunges Despite Furoscix's FDA Approval Zacks
11:49AM	Iovance (IOVA) Doses First Patient in TIL Cancer Therapy Study Zacks
Oct-04-22 08:00AM	Aridis Announces the Closing of Patient Enrollment in the AR-301 Global Phase 3 Superiority Study PR Newswire
Sep-27-22 09:20AM	Aridis Pharmaceuticals Announces Withdrawal of Public Offering of Common Stock PR Newswire -14.28%
Sep-26-22 03:37PM	Aridis Pharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire -29.73%
Sep-21-22 11:39AM	Wave Therapeutics (WVE) Up on Update From Huntington's Study Zacks
Sep-19-22 12:15PM	Intellia (NTLA) Reports Positive Results for CRISPR Candidates Zacks -12.87%
11:58AM	bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD Zacks
Aug-16-22 05:25PM	Aridis Pharmaceuticals (ARDS) Reports Q2 Loss, Misses Revenue Estimates Zacks -6.85%
04:15PM	Aridis Pharmaceuticals Announces Second Quarter 2022 Financial Results and Business Update PR Newswire
Aug-10-22 10:40AM	Aridis' Inhaled Pan-Coronavirus Antibody Cocktail Shows Encouraging Preclinical Action Benzinga
08:30AM	Aridis' Pan-Coronavirus, Inhaled Monoclonal Antibody Cocktail AR-701 Is Protective in Non-Human Primates PR Newswire
10:56AM	Loading…
Jul-01-22 10:56AM	Pfizer (PFE) Seeks FDA Nod for Its Oral Antiviral COVID Pill Zacks
09:55AM	Here's Why Aridis Pharmaceuticals (ARDS) Looks Ripe for Bottom Fishing Zacks
Jun-30-22 11:49AM	Why Endo (ENDP) Stock Wilted After its Surge on Tuesday? Zacks
09:00AM	RedChip Interviews Aridis Pharmaceuticals' CEO Vu Truong ACCESSWIRE
Jun-03-22 08:00AM	Aridis Pharmaceuticals CEO to Participate in a Fireside Chat Presented by Maxim Group LLC and Hosted by M-Vest on June 7 PR Newswire
May-16-22 05:45PM	Aridis Pharmaceuticals (ARDS) Reports Q1 Loss, Lags Revenue Estimates Zacks +13.61%
04:05PM	Aridis Pharmaceuticals Announces First Quarter 2022 Financial Results and Business Update PR Newswire
Mar-31-22 06:04PM	Aridis Pharmaceuticals Announces 2021 Fourth Quarter and Year-End Financial Results and Business Update PR Newswire
Feb-17-22 11:41AM	Aridis Pharma COVID-19 Antibody Neutralizes Omicron Variant In Animal Study Benzinga
06:45AM	Aridis' Pan-Coronavirus Monoclonal Antibody Cocktail AR-701 Is Protective in COVID-19 Omicron Infected Animals PR Newswire
Jan-27-22 06:45AM	Aridis Pharmaceuticals Receives Funding to Evaluate Inhaled Monoclonal Antibodies to Block Influenza and SARS-CoV-2 Transmission PR Newswire +15.52%
Dec-29-21 06:05AM	H.C. Wainwright Bullish on Aridis Pharmaceuticals Covid-19 Antibody Cocktail Investing.com -7.76%
Dec-21-21 02:55PM	Aridis Pharmaceuticals CEO Discusses Monoclonal Antibody Cocktail Protection Against COVID-19 Omicron Variant and Other Viruses in Fox Business Interview PR Newswire +9.45%
12:10PM	ARDS Stock Alert: The Covid-19 News Sending Aridis Skyrocketing Today InvestorPlace
07:16AM	Aridis Pharmaceuticals Surges as Antibody Cocktail Works Against Omicron Investing.com
04:11AM	Aridis Pharmaceuticals Announces a Pan-Coronavirus Monoclonal Antibody Cocktail That Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS, and the Common Cold Human Coronaviruses PR Newswire
Nov-15-21 10:42AM	New Strong Sell Stocks for November 15th Zacks
Nov-12-21 04:45AM	Can Aridis Pharmaceuticals (NASDAQ:ARDS) Afford To Invest In Growth? Simply Wall St.
Nov-10-21 08:00AM	Aridis Pharmaceuticals Announces Third Quarter 2021 Results PR Newswire
Aug-12-21 09:00AM	Aridis Pharmaceuticals Announces Second Quarter 2021 Results PR Newswire
Aug-03-21 03:00PM	Analysts Estimate ARIDIS PHARMACT (ARDS) to Report a Decline in Earnings: What to Look Out for Zacks -10.10%
Aug-02-21 08:00AM	Aridis Pharmaceuticals Announces $25 Million Registered Direct Offering Priced at a Premium to Market PR Newswire
Jul-26-21 08:30AM	Aridis Pharmaceuticals' COVID mAb Ranks Among the Top 5 Most Potent COVID-19 mAbs Evaluated by the Coronavirus Immunotherapeutics Consortium (CoVIC) PR Newswire
Jul-19-21 08:30AM	Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca PR Newswire -14.53%
Jul-13-21 12:22PM	Aridis' (ARDS) COVID Antibody Combo Neutralizes Delta Variant Zacks -16.85%
06:41AM	Aridis Pharma's COVID-19 Antibody Neutralizes Delta Variant In Animal Model Benzinga
Jul-12-21 04:05PM	Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant PR Newswire
Jun-30-21 04:04AM	When Can We Expect A Profit From Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS)? Simply Wall St.
Jun-09-21 09:21AM	Strength Seen in ARIDIS PHARMACT (ARDS): Can Its 10% Jump Turn into More Strength? Zacks
May-11-21 04:01PM	Aridis Pharmaceuticals Announces First Quarter 2021 Results PR Newswire
Mar-30-21 05:49PM	Aridis Pharmaceuticals Announces 2020 Fourth Quarter and Year-End Financial Results and Business Update PR Newswire
Mar-26-21 08:00AM	Aridis Pharmaceuticals Interview to Air on Bloomberg Television U.S. on the RedChip Money Report® PR Newswire +7.44%
Mar-08-21 07:30AM	Aridis Enters into APEX Licensing and Product Discovery Agreement for Zoonotic Viruses with Kermode PR Newswire +12.45%
Feb-23-21 07:25AM	The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga -7.03%
07:21AM	Aridis Pharma To Test Inhaled Antibody Cocktail In COVID-19 Variants Benzinga
05:30AM	Aridis Pharmaceuticals Provides Multiple Program Updates Including the Addition of a Second Inhaled Antibody to Neutralize Newly Emerging COVID-19 Mutated Variants PR Newswire
Feb-16-21 11:56PM	Aridis Pharmaceuticals (NASDAQ:ARDS) Shareholders Have Enjoyed A 32% Share Price Gain Simply Wall St.
Nov-24-20 05:30AM	Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020 PR Newswire
Nov-20-20 04:05PM	Aridis Pharmaceuticals Announces Third Quarter 2020 Results PR Newswire +5.03%
Oct-27-20 04:24PM	/C O R R E C T I O N -- Aridis Pharmaceuticals, Inc./ PR Newswire
Oct-19-20 08:30AM	Aridis Pharmaceuticals Reports Positive Preclinical Efficacy Data of a Highly Effective Inhaled Treatment Supporting a Proposed Self-Administered Therapy for COVID-19 Patients PR Newswire
Oct-14-20 05:30AM	Aridis Pharmaceuticals Announces $8.5 Million Registered Direct Offering PR Newswire
Sep-08-20 05:30AM	Aridis Announces Agreement with the FDA on Updated Phase 2 Clinical Trial Design for AR-501 PR Newswire +10.95%
Sep-04-20 01:32PM	Aridis Pharmaceuticals to Present at Upcoming Investor Conferences PR Newswire
Aug-11-20 04:05PM	Aridis Pharmaceuticals Announces Second Quarter 2020 Results PR Newswire -5.51%
Jul-15-20 08:42AM	We Think Aridis Pharmaceuticals (NASDAQ:ARDS) Can Easily Afford To Drive Business Growth Simply Wall St. -6.36%
Jun-26-20 05:30AM	Aridis Pharmaceuticals to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19 PR Newswire +6.06%
Jun-22-20 05:30AM	Aridis Reports AR-501 Clinical Data: Positive Safety Data in Healthy Subjects of a Phase 1/2a Clinical Trial PR Newswire
Jun-18-20 05:30AM	Aridis Pharmaceuticals to Discuss APEX in Virtual Fireside Chat Hosted by Cantor Fitzgerald on June 25th PR Newswire +7.52%
Jun-15-20 05:30AM	Aridis Pharmaceuticals Appoints Dr. Hasan Jafri as Chief Medical Officer PR Newswire
May-12-20 04:05PM	Aridis Pharmaceuticals Announces First Quarter 2020 Results PR Newswire
May-07-20 12:08PM	Will Aridis Pharmaceuticals Continue to Surge Higher? Zacks
May-04-20 05:30AM	Aridis Pharmaceuticals Enrolls Its First COVID-19 Patient in Ongoing Phase 3 AR-301 Clinical Trial in Ventilator Associated Pneumonia (VAP) PR Newswire +22.74%
Apr-29-20 05:30AM	Aridis Pharmaceuticals to Participate in Maxim Group's Infectious Disease Virtual Conference PR Newswire
Apr-15-20 02:28PM	Can Aridis Pharmaceuticals APEX Platform Be Used to Target Coronavirus? Analyst Weighs In TipRanks
Apr-08-20 04:59PM	Aridis Pharmaceuticals Announces 2019 Fourth Quarter and Year-End Financial Results and Business Update PR Newswire
Mar-06-20 04:05PM	Aridis Pharmaceuticals to Postpone Investor Day Due to Coronavirus Concerns PR Newswire
Mar-05-20 05:30AM	Aridis Pharmaceuticals to Present at the 32nd Annual ROTH Conference PR Newswire -6.20%
Mar-04-20 05:30AM	Aridis Pharmaceuticals Provides Update on Investor Day Featuring Key Opinion Leader Panels on Cystic Fibrosis and Pneumonia PR Newswire
Feb-28-20 02:15PM	San Jose biotech incubator where Impossible Foods hatched expands at new site American City Business Journals
Feb-18-20 05:30AM	Aridis Pharmaceuticals to Host Investor Day Showcasing APEX Technology Platform and Key Opinion Leader Panels on Cystic Fibrosis and Pneumonia PR Newswire +5.44%
Jan-28-20 02:56PM	Aridis Pharmaceuticals Presents APEX Antibody Discovery and Production Platform Technology at the 19th Annual CHI PepTalk Conference PR Newswire
Jan-17-20 05:34AM	We're Hopeful That Aridis Pharmaceuticals (NASDAQ:ARDS) Will Use Its Cash Wisely Simply Wall St.
Jan-03-20 02:44PM	3 Beaten-Up Biotech Stocks That Just Got More Enticing TipRanks
Jan-02-20 08:46AM	The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe Benzinga
05:30AM	Aridis Pharmaceuticals Appoints Michael A. Nazak as Chief Financial Officer PR Newswire
Nov-13-19 04:05PM	Aridis Pharmaceuticals Announces Third Quarter 2019 Results PR Newswire
Oct-19-19 08:47AM	Introducing Aridis Pharmaceuticals (NASDAQ:ARDS), The Stock That Slid 52% In The Last Year Simply Wall St.
Oct-11-19 05:30AM	Aridis Pharmaceuticals Appoints Infectious Disease Expert Paul Mendelman, MD as Interim Chief Medical Officer PR Newswire
Sep-30-19 05:30AM	Aridis Pharmaceuticals Executes License Agreement with The Serum Institute of India, Ltd. for Exclusive Rights to Products and Utilization of MabIgX® Platform Technology PR Newswire

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience